20
Participants
Start Date
January 31, 2007
Primary Completion Date
January 31, 2009
ibritumomab tiuxetan (Zevalin)
During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count \> 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
Chonnam National University Hwasun Hospital, Hwasun-gun
Collaborators (1)
Samsung Medical Center
OTHER
Asan Medical Center
OTHER
Chonbuk National University Hospital
OTHER
Dong-A University Hospital
OTHER
Pusan National University Hospital
OTHER
Severance Hospital
OTHER
Chonnam National University Hospital
OTHER